J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study
Reuters
Published Oct 13, 2021 03:58PM ET
Updated Oct 14, 2021 12:40AM ET
By Carl O'Donnell
(Reuters) - People who got Johnson & Johnson (NYSE:JNJ) Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer (NYSE:PFE) Inc/BioNTech SE or Moderna (NASDAQ:MRNA) Inc, a study run by the National Institutes of Health showed on Wednesday.
The study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&J's efforts to use its COVID-19 vaccine as a booster in the United States.
The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that "mixing and matching" booster shots of different types is safe in adults. Moderna's and Pfizer's vaccines are based on messenger RNA while J&J's uses viral vector technology.
It comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&J vaccines.
FDA officials on Wednesday said J&J's regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.
U.S. health officials have been under pressure to offer advice on booster doses of the J&J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.
The NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.
Mixing and matching doses for a booster produced similar side effects to those seen in primary inoculations and raised no significant safety concerns, the study said.
The study of the three COVID-19 vaccines currently authorized in the United States showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type.
Get The News You Want
The trial took place in 10 U.S. cities and used a total of nine combinations of initial shots and boosters.
Mixing booster doses "may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines," researchers wrote in the study.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.